Mon, November 7, 2022
Fri, November 4, 2022
Thu, November 3, 2022

Matthew Sykes Maintained (CDNA) at Strong Buy with Decreased Target to $40 on, Nov 4th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-40-on-nov-4th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Sykes of Goldman Sachs, Maintained "CareDx, Inc" (CDNA) at Strong Buy with Decreased Target from $45 to $40 on, Nov 4th, 2022.

Matthew has made no other calls on CDNA in the last 4 months.



There is 1 other peer that has a rating on CDNA. Out of the 1 peers that are also analyzing CDNA, 0 agree with Matthew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Matthew


  • Andrew Cooper of "Raymond James" Maintained at Strong Buy with Decreased Target to $35 on, Wednesday, August 10th, 2022

Publication Contributing Sources